Program
AZD2389
A development code.
Its studies are mostly in Liver Cirrhosis · Lymphoma, Follicular · Liver Diseases, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 81 open or running | phase 2since Dec 6, 2024 | Nov 14, 2023 | Jul 7, 2027phase 2 · NCT07610837 |
- Named in AstraZeneca’s own pipeline as
AZD2389
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: ctc-clinical-trial-consultants-ab and parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2023First study: phase 1 study in Liver DiseasesFirst studyNCT06138795 · 120 enrolled · United States
- Dec 6, 2024Phase 2 study in Liver CirrhosisNCT06750276 · 40 enrolled · United States, Puerto Rico, United Kingdom
- Feb 3, 20252 phase 1 studiesNCT06812780, NCT06846528
- May 7, 20253 phase 1 studies in Liver CirrhosisNCT06973005, NCT06974565, NCT07069725
- Apr 30, 2026Phase 2 study in Liver CirrhosisNCT07610837 · 104 planned · United States, Puerto Rico
Ahead
- Jul 7, 2027Primary completion: phase 2 study in Liver CirrhosisNCT07610837
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07610837Liver Cirrhosis · United States, Puerto Rico | 2 | Recruiting | Jul 7, 2027 | 104 |
| NCT07069725Liver Cirrhosis · Sweden | 1 | Completed | Jul 2, 2026 | 8 |
| NCT06974565Liver Cirrhosis · United States | 1 | Completed | Jul 18, 2025 | 16 |
| NCT06973005Liver Cirrhosis · United States | 1 | Completed | Jul 18, 2025 | 16 |
| NCT06846528Healthy Participants · United States | 1 | Completed | Apr 23, 2025 | 16 |
| NCT06812780Lymphoma, Follicular · United States | 1 | Completed | Sep 4, 2025 | 35 |
| NCT06750276Liver Cirrhosis · United States, Puerto Rico, United Kingdom | 2 | Completed | Jul 28, 2025 | 40 |
| NCT06138795Liver Diseases · United States | 1 | Completed | Aug 24, 2025 | 120 |
How it is read
Names in the registry
- “AZD2389”, 8 entries
Codes read as this program: AZD2389.
Conditions, from the studies’ own filings
- Liver Cirrhosis, 5 studies
- Lymphoma, Follicular, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.